Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

COSCIENS Biopharma Inc (CSCI)

NASDAQ
Symbol
Exchange
Currency
CSCITorontoCAD
CSCINASDAQUSD
0UGBLondonCAD
ET8FrankfurtEUR
Currency in USD
2.6629
-0.1505(-5.35%)
Closed
After Hours
2.6700+0.0071(+0.2666%)
CSCI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
2.63702.8700
52 wk Range
2.620011.1000
Key Statistics
Edit
Prev. Close
2.8134
Open
2.87
Day's Range
2.637-2.87
52 wk Range
2.62-11.1
Volume
3.35K
Average Volume (3m)
5.57K
1-Year Change
-69.74%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CSCI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 13
Net income is expected to grow this year
Unlock InvestingPro

COSCIENS Biopharma Inc News & Analysis

Show more

COSCIENS Biopharma Inc Company Profile

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
12
Market
Canada

Compare CSCI to Peers and Sector

Metrics to compare
CSCI
Peers
Sector
Relationship
P/E Ratio
−0.4x−6.7x−0.6x
PEG Ratio
0.02−0.180.00
Price/Book
0.4x3.2x2.6x
Price / LTM Sales
1.8x7.0x3.2x
Upside (Analyst Target)
-206.1%46.2%
Fair Value Upside
Unlock0.9%7.0%Unlock

FAQ

What Is the COSCIENS Biopharma (CSCI) Stock Price Today?

The COSCIENS Biopharma stock price today is 2.6629.

What Stock Exchange Does COSCIENS Biopharma Trade On?

COSCIENS Biopharma is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for COSCIENS Biopharma?

The stock symbol for COSCIENS Biopharma is "CSCI."

What Is the COSCIENS Biopharma Market Cap?

As of today, COSCIENS Biopharma market cap is 8.55M.

What is COSCIENS Biopharma Earnings Per Share?

The COSCIENS Biopharma EPS is -14.28.

From a Technical Analysis Perspective, Is CSCI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.